

Resource Summary Report

Generated by [RRID](#) on Aug 20, 2026

pHL-EF1a-SphcCas9-iP-A

RRID:Addgene_60599

Type: Plasmid

Proper Citation

RRID:Addgene_60599

Plasmid Information

URL: <http://www.addgene.org/60599>

Proper Citation: RRID:Addgene_60599

Insert Name: CRISPR Cas9

Organism: Streptococcus pyogenes

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:25434822](#)

Vector Backbone Description: Backbone Marker:Hotta Lab, CiRA; Backbone Size:6923; Vector Backbone:pHL-EF1a-GW-iP-A; Vector Types:Mammalian Expression, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: pHL-EF1a-SphcCas9-iP-A

Relevant Mutation: Codon usage optimized for human usage

Record Creation Time: 20220422T222348+0000

Record Last Update: 20260815T081734+0000

Ratings and Alerts

No rating or validation information has been found for pHL-EF1a-SphcCas9-iP-A.

No alerts have been found for pHL-EF1a-SphcCas9-iP-A.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Park SB, et al. (2026) Human pluripotent stem cell engineering with CRISPR-Cas9 for Parkinson's disease. *Experimental & molecular medicine*, 58(4), 993.

Uno N, et al. (2024) Microcell-mediated chromosome transfer between non-identical human iPSCs. *Molecular therapy. Nucleic acids*, 35(4), 102382.

Sanchez-Martin A, et al. (2023) Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 165, 115209.

Ueda T, et al. (2023) Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. *Nature biomedical engineering*, 7(1), 24.

Nishitani-Isa M, et al. (2022) Trapping of CDC42 C-terminal variants in the Golgi drives pyrin inflammasome hyperactivation. *The Journal of experimental medicine*, 219(6).

Fukuta M, et al. (2021) Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model. *Lupus science & medicine*, 8(1).

Yokota M, et al. (2021) Establishment of an in vitro model for analyzing mitochondrial ultrastructure in PRKN-mutated patient iPSC-derived dopaminergic neurons. *Molecular brain*, 14(1), 58.

Takahashi K, et al. (2020) Critical Roles of Translation Initiation and RNA Uridylation in Endogenous Retroviral Expression and Neural Differentiation in Pluripotent Stem Cells. *Cell reports*, 31(9), 107715.

Hirosawa M, et al. (2019) Cell-Type-Specific CRISPR Activation with MicroRNA-Responsive AcrIIA4 Switch. *ACS synthetic biology*, 8(7), 1575.

Ishii T, et al. (2019) In Vitro Modeling of the Bipolar Disorder and Schizophrenia Using Patient-Derived Induced Pluripotent Stem Cells with Copy Number Variations of PCDH15 and RELN. *eNeuro*, 6(5).

Sasaki-Honda M, et al. (2018) A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4. *Human molecular genetics*, 27(23), 4024.

Hirosawa M, et al. (2017) Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. *Nucleic acids research*, 45(13), e118.

Arsenault PR, et al. (2016) Identification of Small-Molecule PHD2 Zinc Finger Inhibitors that Activate Hypoxia Inducible Factor. *Chembiochem : a European journal of chemical biology*, 17(24), 2316.

Li HL, et al. (2016) Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system. *Methods (San Diego, Calif.)*, 101, 27.